- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06216561
Intraperitoneal LSTA1 in CRS-HIPEC
A Phase I Trial of Intraperitoneal LSTA1 in Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy
Study Overview
Status
Intervention / Treatment
Detailed Description
Given the high recurrence and disease-related mortality in patients with peritoneal metastases from appendiceal, colorectal, and ovarian cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), use of an agent to improve operative tumor delivery of co-administered anticancer drugs during HIPEC would potentially have significant impact on oncologic outcomes.
Safety of LSTA1 has been demonstrated in the context of metastatic pancreatic cancer when administered intravenously with cytotoxic chemotherapy, but the investigators wish to determine its safety and potential efficacy when administered intraperitoneally with HIPEC in patients with peritoneal metastases from appendiceal, colorectal, and ovarian cancer.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Joel Baumgartner
- Phone Number: (858) 246-0581
- Email: J1baumgartner@health.ucsd.edu
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- University of California San Diego
-
Contact:
- John Bienvenida
- Phone Number: 858-822-4907
- Email: jbienvenida@health.ucsd.edu
-
Principal Investigator:
- Joel Baumgartner
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Participants must have histologically confirmed non-mucinous (< 50% mucin) colorectal, ovarian, or appendiceal carcinoma with peritoneal metastases who are candidates for (cytoreductive surgery and CRS-HIPEC and have at least one peritoneal tumor nodule > 5 mm (as determined by routine preoperative imaging and confirmed by intraoperative assessment).
- Eligible and intended to undergo CRS-HIPEC per the investigators. This includes assessment of axial imaging (computed tomography, magnetic resonance imaging, positron emission tomography scan) of chest, abdomen, and pelvis, within 30 days of screening, which reveals peritoneal metastases amenable to complete cytoreduction per the investigators (i.e. limited small bowel/mesenteric metastases), lack of extra-peritoneal metastases (including intra-hepatic and pulmonary metastases), and lack of untreated biliary, gastrointestinal, and urologic obstruction.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status < 2.
- Women of child-bearing potential with negative pregnancy test prior to undergoing CRS-HIPEC.
- Adequate contraception for participants able to cause a pregnancy:
Exclusion Criteria:
- Participants who do not receive HIPEC at the time of CRS.
- Any major surgery or irradiation within 30 days prior to prior to planned date of CRS-HIPEC.
- Active infection (viral, fungal, or bacterial) requiring systemic therapy.
- Known active hepatitis B virus (HBV), hepatitis C virus (HCV), tuberculosis, or human immunodeficiency virus (HIV) infection.
- History of allogeneic tissue/solid organ transplant.
- History or clinical evidence of central nervous system (CNS) metastases without exceptions
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to LSTA1 or other agents used in the study, including those discovered by other ongoing studies of LSTA1 or other agents used in the study.
- Existing venous thromboembolism at the time of CRS-HIPEC.
Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to undergo CRS-HIPEC and receive study treatment. This includes, but is not limited to the following laboratory values and other parameters within 30 days prior to planned date of CRS-HIPEC:
- Platelets < 100,000/mm3
- White blood cell count < 3000/ mm3
- Absolute neutrophil count < 1,500/mm3
- Serum albumin < 2.5 g/L
- Alanine transaminase (ALT) and aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN) in the absence of liver metastases or > 5 x ULN in the presence of liver metastases
- Bilirubin > 1.5 x ULN
- Glomerular Filtration Rate (per Modification of Diet in Renal Disease equation) < 30 mL/min
- Hemoglobin < 9.0 g/dL (drawn 24 hours after a transfusion, if relevant)
- International normalised ratio (INR) > 2.0 (for patients not receiving therapeutic anticoagulation)
- Adequate respiratory and cardiac function (PaO2 ≥ 60 mm Hg or oxygen saturation ≥ 92% on room air, and 12-lead electrocardiogram (ECG) with normal tracing or QT interval < 470 ms)
- Participants who are pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRS-HIPEC + LSTA1
Experimental Arm
|
LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
|
Active Comparator: CRS-HIPEC alone
Control Arm
|
Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events of interest (AE-I)
Time Frame: postoperatively from the date of CRS-HIPEC to date of discharge (typically 1-2 weeks)
|
The proportion of subjects experiencing an inpatient adverse event of interest (AE-I; gastrointestinal fistula/leak, neutropenia, intra-abdominal abscess, venous thromboembolism, mortality)
|
postoperatively from the date of CRS-HIPEC to date of discharge (typically 1-2 weeks)
|
Drug concentration in tumor
Time Frame: at time of surgery
|
Total drug content in tumor, divided by total tumor mass
|
at time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival and Overall Survival
Time Frame: 5 years
|
Time (in months) from randomization to time of progression or death due to any cause, whichever occurs first (PFS), or to time of death due to any cause (OS).
|
5 years
|
Adverse Events (AEs)
Time Frame: 30 Days
|
Incidence of any adverse events (AEs) by grade and system organ class using CTCAE v5.0 up to 30 days from the date of CRS-HIPEC.
|
30 Days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joel Baumgartner, University of California, San Diego
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCSD 807804
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on CRS-HIPEC + LSTA1
-
CAI HongbingRecruitingOvarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer, Epithelial | Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | Homologous Recombination Repair Gene MutationChina
-
University of ZurichUnknownPeritoneal CancerSwitzerland
-
Uppsala University HospitalCompletedColorectal Cancer, Peritoneal Carcinomatosis, Anastomosis InsufficiencySweden
-
Shu-Zhong CuiGuangdong Provincial Hospital of Traditional Chinese Medicine; Chinese PLA... and other collaboratorsUnknownGastric Cancer | Peritoneal CarcinomatosisChina
-
Yonsei UniversityCompletedGastric Cancer With Peritoneal Metastasis (PCI<12)Korea, Republic of
-
Zhongnan HospitalActive, not recruitingOvarian Neoplasms | Ovarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer, Epithelial | Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | Ovary NeoplasmChina
-
Milton S. Hershey Medical CenterTerminatedGynecologic Cancer | Ovarian Cancer | Colon Cancer | GI CancerUnited States
-
National Cancer Institute (NCI)WithdrawnPeritoneal Carcinomatosis | Colorectal CarcinomaUnited States
-
A.O. Ospedale Papa Giovanni XXIIIClinical Organization for Strategies & Solutions (CLIOSS), former Nerviano... and other collaboratorsUnknown
-
Sun Yat-sen UniversityNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Peritoneal Neoplasms | Colorectal Cancer Metastatic | Chemotherapy Effect | Cytoreductive Surgery | Peritoneal Cancer | Peritoneal Metastases | Hyperthermic Intraperitoneal ChemotherapyChina